logo-loader
viewDyadic International Inc

Dyadic 'advancing the ball down the field' with Wall St, and its C1 gene expression platform

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb sat down with Proactive at the BIO Investor Forum in San Francisco. 

Analysts at Dawson James Securities recently initiated coverage on Dyadic with a Buy rating citing the effectiveness of the biotechnology company’s C1 gene expression platform.

Quick facts: Dyadic International Inc

Price: 5.32 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $144.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Dyadic CEO remarks on steps the federal gov't can take to speed along drug...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb sat down with Proactive at the Biotech Showcase 2020 in San Francisco. Emalfarb talks about how there's a lot of things the government can do to speed the development of new biologics to the market. Namely, by offering a simliar orphan...

on 01/16/2020

2 min read